Alternatively, drug repositioning with FDA-approved protein kinase inhibitors may facilitate the process of drug development for CNS disorders, such as the recently demonstrated beneficial effect of c-Abl inhibitors in AD and PD (Miller et al., 2012). Here, ABL1 is linked to Parkinson disease.